Preprint
Case Report
Deteriorating Atrioventricular Block in COVID-19 Suspected Patient after Receiving Initial Dose of Azythromycin and Hydroxychloroquine
Altmetrics
Downloads
530
Views
669
Comments
0
This version is not peer-reviewed
Preprints on COVID-19 and SARS-CoV-2
Submitted:
09 May 2020
Posted:
11 May 2020
You are already at the latest version
Alerts
Abstract
Coronavirus 2019 (COVID-19) is an infectious disease that is becoming a pandemic. Hydroxychloroquine in combination with azythromycin are among drugs currently in use to eradicate COVID-19. Despite concerns due to its potential cardiac toxicity, hydroxychloroquine is widely accepted in mild and moderate COVID-19 pneumonia. In this case report, we report a case of a young Indonesian adult male with suspected COVID-19 pneumonia who received hydroxychloroquine and azythromycin therapies and during 24 hour experienced deterioration of atrioventricular block.
Keywords:
Subject: Medicine and Pharmacology - Cardiac and Cardiovascular Systems
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
MDPI Initiatives
Important Links
© 2024 MDPI (Basel, Switzerland) unless otherwise stated